TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12806564

Group type: EXPERIMENTAL
Intervention: Systematic review and meta-analysis procedures
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Meta-analysis procedures
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Inverse variance method
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Validity assessment of systematic reviews
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Application of systematic review results
Number of subjects: 0
Study: 10934782

Group type: EXPERIMENTAL
Intervention: Ceftazidim (CTZ) 1 g i.v.
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (CPF) 400 mg i.v.
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Clindamycin (CLIN) 900 mg i.v.
Number of subjects: 75
Study: 9241108

Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfamethoxazole
Number of subjects: 1484

Group type: EXPERIMENTAL
Intervention: Dapsone/pyrimethamine
Number of subjects: 1484
Study: 1584258

Group type: EXPERIMENTAL
Intervention: Endoscopic biliary drainage
Number of subjects: 82
Study: 3882617

Group type: EXPERIMENTAL
Intervention: Iohexol
Number of subjects: 277

Group type: COMPARATOR
Intervention: Ionic media (meglumine iothalamate and meglumine-Na diatrizoate)
Number of subjects: 277

Group type: EXPERIMENTAL
Intervention: All media studied (including iohexol and ionic media)
Number of subjects: 277
Study: 29276844

Group type: EXPERIMENTAL
Intervention: Exercise and diet interventions
Number of subjects: 69

Group type: COMPARATOR
Intervention: Exercise intervention (Control)
Number of subjects: 69
Study: 29150857

Group type: EXPERIMENTAL
Intervention: 170 μg LPP
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: 370 μg LPP
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: 70 μg LPP
Number of subjects: 198

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: All treatment groups (70 μg, 170 μg, 370 μg)
Number of subjects: 198
Study: 25927221

Group type: EXPERIMENTAL
Intervention: Stepwise tapering of remifentanil from 0.3 to 0.1 μg/kg/min for at least 30 minutes (Group B)
Number of subjects: 62

Group type: COMPARATOR
Intervention: High-dose remifentanil infused at 0.3 μg/kg/min until the end of surgery (Group A)
Number of subjects: 62
Study: 23565623

Group type: EXPERIMENTAL
Intervention: Visually paced breathing at 0.14 Hz
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Visually paced breathing at 0.10 Hz
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Visually paced breathing at 0.06 Hz
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Resting frequency
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Deep and slow breathing (DSB)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Baseline-to-DSB and session-to-session differences in RR-interval
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: SDRR and respiratory CO2
Number of subjects: 20
Study: 21320737

Group type: EXPERIMENTAL
Intervention: Glucomannan (GNN) 2.52 g/d for 4 weeks
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo for 4 weeks
Number of subjects: 80
Study: 19590588

Group type: EXPERIMENTAL
Intervention: Statins
Number of subjects: 0
Study: 17420403

Group type: EXPERIMENTAL
Intervention: Retigabine 600 mg/day
Number of subjects: 399

Group type: EXPERIMENTAL
Intervention: Retigabine 900 mg/day
Number of subjects: 399

Group type: EXPERIMENTAL
Intervention: Retigabine 1,200 mg/day
Number of subjects: 399

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 399
Study: 15482042

Group type: EXPERIMENTAL
Intervention: Abstinence reinforcement with take-home methadone doses for opiate- and cocaine-free urine samples
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Abstinence reinforcement with take-home methadone doses and 5,800 US dollars in vouchers for cocaine-free urine samples
Number of subjects: 78

Group type: COMPARATOR
Intervention: Usual care control group
Number of subjects: 78
Study: 11470017

Group type: EXPERIMENTAL
Intervention: Angiotensin converting enzyme inhibitors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Calcium antagonists
Number of subjects: 0
Study: 7892015

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral (CB) intervention followed by usual TMD treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual TMD treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral (CB) intervention
Number of subjects: 0
Study: 3362846

Group type: EXPERIMENTAL
Intervention: Intragastric beer
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Intrajejunal beer
Number of subjects: 14

Group type: COMPARATOR
Intervention: Glucose (5.6%, w/v) intragastrically
Number of subjects: 14

Group type: COMPARATOR
Intervention: Glucose (5.6%, w/v) intrajejunally
Number of subjects: 14
Study: 30070567

Group type: EXPERIMENTAL
Intervention: Oxytocin (24 IU)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 27914651

Group type: EXPERIMENTAL
Intervention: Individualised functional restoration plus guideline-based advice
Number of subjects: 96

Group type: COMPARATOR
Intervention: Advice alone
Number of subjects: 96
Study: 25877340

Group type: EXPERIMENTAL
Intervention: Structured Planning
Number of subjects: 2565

Group type: COMPARATOR
Intervention: Rapid Implementation
Number of subjects: 2565
Study: 23193208

Group type: EXPERIMENTAL
Intervention: Assessment of barriers to self-care and strategies to cope with these barriers
Number of subjects: 100

Group type: COMPARATOR
Intervention: Attention control (usual care)
Number of subjects: 100
Study: 21255059

Group type: EXPERIMENTAL
Intervention: Delayed-release mesalazine 4.8 g/day
Number of subjects: 391

Group type: COMPARATOR
Intervention: Delayed-release mesalazine 2.4 g/day
Number of subjects: 391
Study: 18287365

Group type: EXPERIMENTAL
Intervention: Vitamin group (n = 127) took a daily supplement containing 1000 microg folate, 500 microg vitamin B‐12, and 10 mg vitamin B‐6 for 2 years
Number of subjects: 253

Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 253
Study: 16943535

Group type: EXPERIMENTAL
Intervention: Prostate cancer treatment (surgery, radiotherapy, watchful waiting, hormone therapy)
Number of subjects: 2211

Group type: EXPERIMENTAL
Intervention: Radical prostatectomy
Number of subjects: 2211
Study: 14584860

Group type: EXPERIMENTAL
Intervention: rhPDGF-BB (0.5 mg/ml, 1.0 mg/ml, or 5.0 mg/ml) with demineralized freeze-dried bone allograft (DFDBA)
Number of subjects: 9

Group type: COMPARATOR
Intervention: ABB-C (anorganic bovine bone in collagen) with a bilayer collagen membrane
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: rhPDGF/allograft
Number of subjects: 9

Group type: COMPARATOR
Intervention: ABB-C and membrane
Number of subjects: 9
Study: 10930195

Group type: EXPERIMENTAL
Intervention: Urapidil
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 9282197

Group type: EXPERIMENTAL
Intervention: 5% cocaine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 5% cocaine and normal saline (both sides)
Number of subjects: 60
Study: 8494508

Group type: EXPERIMENTAL
Intervention: Diflunisal
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 2893417

Group type: EXPERIMENTAL
Intervention: 0.02 mg/kg IV lormetazepam
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 0.03 mg/kg IV Ro 15-1788
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Lormetazepam
Number of subjects: 30

Group type: COMPARATOR
Intervention: Drug-free control group
Number of subjects: 30
Study: 28563995

Group type: EXPERIMENTAL
Intervention: FLACS BT
Number of subjects: 343

Group type: EXPERIMENTAL
Intervention: FLACS TT
Number of subjects: 343

Group type: COMPARATOR
Intervention: Manual BT
Number of subjects: 343

Group type: COMPARATOR
Intervention: Manual TT
Number of subjects: 343
Study: 26655398

Group type: EXPERIMENTAL
Intervention: 10 g/day RS2 for 8 weeks
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo for 8 weeks
Number of subjects: 56
Study: 25694060

Group type: EXPERIMENTAL
Intervention: Imeglimin 1500 mg twice daily for 1 week
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study: 23930213

Group type: EXPERIMENTAL
Intervention: Thalidomide 100-200 mg/day
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study: 20211108

Group type: EXPERIMENTAL
Intervention: Septoplasty
Number of subjects: 14
Study: 18400715

Group type: EXPERIMENTAL
Intervention: alpha-lactalbumin-enriched formula (25% of protein, glycomacropeptide 15% or 10%)
Number of subjects: 96

Group type: COMPARATOR
Intervention: standard formula
Number of subjects: 96

Group type: COMPARATOR
Intervention: all formula-fed infants
Number of subjects: 96

Group type: COMPARATOR
Intervention: all groups (formula-fed)
Number of subjects: 96
Study: 16845254

Group type: EXPERIMENTAL
Intervention: Bezafibrate
Number of subjects: 3090

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3090
Study: 12587106

Group type: EXPERIMENTAL
Intervention: Pattern mixture model for longitudinal quality of life (QOL) data analysis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Exploratory data techniques for longitudinal QOL data
Number of subjects: 0
Study: 11020392

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (50 mg per day)
Number of subjects: 185

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 185
Study: 8648286

Group type: EXPERIMENTAL
Intervention: Graph interpretation with slope-mapping constraint honored (variable assigned to vertical axis)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Graph interpretation with variable not assigned to vertical axis
Number of subjects: 0
Study: 8447608

Group type: EXPERIMENTAL
Intervention: Dopamine at 200 micrograms/min
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study: 3511958

Group type: EXPERIMENTAL
Intervention: Birthroom (n = 76)
Number of subjects: 148

Group type: COMPARATOR
Intervention: Labour ward (n = 72)
Number of subjects: 148
Study: 29104158

Group type: EXPERIMENTAL
Intervention: Low-sodium diet with paricalcitol (2 μg per day)
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: High-sodium diet with paricalcitol (2 μg per day)
Number of subjects: 115

Group type: COMPARATOR
Intervention: Low-sodium diet with placebo
Number of subjects: 115

Group type: COMPARATOR
Intervention: High-sodium diet with placebo
Number of subjects: 115
Study: 27636349

Group type: EXPERIMENTAL
Intervention: Aerobic Interval Training (AIT)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Nonlinear Resistance Training (NRT)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 33
Study: 24313244

Group type: EXPERIMENTAL
Intervention: Venlafaxine (up to 300 mg/day)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 130
Study: 22047719

Group type: EXPERIMENTAL
Intervention: Treatment sustainers (TS)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Resumed heavy use (RHU)
Number of subjects: 45
Study: 20498120

Group type: EXPERIMENTAL
Intervention: darunavir/ritonavir (800/100 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: lopinavir/ritonavir (800/200 mg)
Number of subjects: 0
Study: 19090910

Group type: EXPERIMENTAL
Intervention: Peri-implantitis sites
Number of subjects: 15

Group type: COMPARATOR
Intervention: Healthy sites
Number of subjects: 15
Study: 15943845

Group type: EXPERIMENTAL
Intervention: Famotidine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mosapride
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tandospirone
Number of subjects: 0
Study: 12600908

Group type: EXPERIMENTAL
Intervention: Clopidogrel (300 mg initially followed by 75 mg/d)
Number of subjects: 12562
Study: 10495970

Group type: EXPERIMENTAL
Intervention: PCQL‐32 short form
Number of subjects: 291
Study: 8901791

Group type: EXPERIMENTAL
Intervention: Dietary lysine intake of 45.0 mg.kg‐1.d‐1
Number of subjects: 5

Group type: COMPARATOR
Intervention: Protein intake of 0.8 g.kg‐1.d‐1
Number of subjects: 5

Group type: COMPARATOR
Intervention: Protein intake of 1.0 g.kg‐1.d‐1
Number of subjects: 5
Study: 1807123

Group type: EXPERIMENTAL
Intervention: Cephalosporin prophylaxis
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Quinolone prophylaxis
Number of subjects: 200

Group type: COMPARATOR
Intervention: No prophylactic antibiotic regime
Number of subjects: 200
Study: 6378045

Group type: EXPERIMENTAL
Intervention: Lorcainide (200 mg daily for ten days after 24 hours of intravenous administration)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Lidocaine (3 mg/min for the first 24 hours) and Pindolol (oral for the following ten days)
Number of subjects: 18
Study: 30838706

Group type: EXPERIMENTAL
Intervention: Boswellia serrata extract (BSE)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 29581124

Group type: EXPERIMENTAL
Intervention: Endovascular treatment (EVT)
Number of subjects: 1488

Group type: EXPERIMENTAL
Intervention: Successful reperfusion after EVT
Number of subjects: 1488
Study: 26362167

Group type: EXPERIMENTAL
Intervention: Personalized daily text messaging intervention
Number of subjects: 105
Study: 24014499

Group type: EXPERIMENTAL
Intervention: Bulimic Investigatory Test Edinburgh (BITE)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Eating Attitudes Test (EAT)
Number of subjects: 0
Study: 22352784

Group type: EXPERIMENTAL
Intervention: Escalating reinforcement condition
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Fixed reinforcement condition
Number of subjects: 133

Group type: COMPARATOR
Intervention: Attendance control condition
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Escalating and fixed conditions combined
Number of subjects: 133
Study: 19578224

Group type: EXPERIMENTAL
Intervention: Intermittent chemotherapy (twice weekly)
Number of subjects: 466

Group type: COMPARATOR
Intervention: Daily chemotherapy
Number of subjects: 466
Study: 18520864

Group type: EXPERIMENTAL
Intervention: Suprafascial dissection
Number of subjects: 27

Group type: COMPARATOR
Intervention: Subfascial dissection
Number of subjects: 27

Group type: COMPARATOR
Intervention: Deep dissection
Number of subjects: 27
Study: 16105532

Group type: EXPERIMENTAL
Intervention: Compression Anastomosis Clip (CAC)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Stapler
Number of subjects: 60
Study: 11823073

Group type: EXPERIMENTAL
Intervention: Double-bolus eptifibatide 180/90 (30 min apart) and 1.33 microg/kg per min infusion with 50 mg t-PA (Group I)
Number of subjects: 649

Group type: EXPERIMENTAL
Intervention: Double-bolus eptifibatide 180/90 (10 min apart) and 2.0 microg/kg per min infusion with 50 mg t-PA (Group II)
Number of subjects: 649
Study: 10730335

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 7486271

Group type: COMPARATOR
Intervention: Nicardipine 0.016 mg.kg‐1
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Magnesium sulfate 50 mg.kg‐1
Number of subjects: 40
Study: 2298002

Group type: EXPERIMENTAL
Intervention: High intravenous glucose infusion
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low intravenous glucose infusion
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Injured or septic patients
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal subjects
Number of subjects: 0
Study: 7459805

Group type: COMPARATOR
Intervention: Halsted mastectomy
Number of subjects: 716

Group type: EXPERIMENTAL
Intervention: Halsted mastectomy with internal mammary node dissection
Number of subjects: 716
Study: 30880334

Group type: EXPERIMENTAL
Intervention: Dasatinib 100 mg and Afatinib 30 mg
Number of subjects: 25
Study: 27768508

Group type: EXPERIMENTAL
Intervention: Whole-body vibration (WBV) training (n = 13)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (CON, n = 15)
Number of subjects: 40
Study: 25943183

Group type: EXPERIMENTAL
Intervention: Group P1: intravenous flurbiprofen and epidural fentanyl + ketamine before surgery
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Group P2: intravenous flurbiprofen before surgery and epidural fentanyl + ketamine after surgery
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Group P3: epidural fentanyl + ketamine before surgery and intravenous flurbiprofen after surgery
Number of subjects: 100

Group type: COMPARATOR
Intervention: Group C: normal saline treatment
Number of subjects: 100
Study: 23712686

Group type: EXPERIMENTAL
Intervention: OA + CPM
Number of subjects: 29

Group type: COMPARATOR
Intervention: OA
Number of subjects: 29

Group type: COMPARATOR
Intervention: CPM
Number of subjects: 29
Study: 21430514

Group type: EXPERIMENTAL
Intervention: Antioxidant (vitamins E and C)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Matching placebos
Number of subjects: 20
Study: 19805651

Group type: EXPERIMENTAL
Intervention: Valsartan
Number of subjects: 5010
Study: 16964557

Group type: EXPERIMENTAL
Intervention: Carotid stenting
Number of subjects: 20

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 20
Study: 15475554

Group type: EXPERIMENTAL
Intervention: Exercise group (82.5 ± 5% of peak heart rate for 9 months)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Exercise group
Number of subjects: 22
Study: 11484687

Group type: EXPERIMENTAL
Intervention: Surgery
Number of subjects: 80

Group type: COMPARATOR
Intervention: Antiepileptic drugs
Number of subjects: 80
Study: 9987256

Group type: EXPERIMENTAL
Intervention: Individualized counseling and education (intervention group)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Nursing Child Assessment Feeding Scale (NCAFS) scores (intervention group)
Number of subjects: 23
Study: 7840398

Group type: EXPERIMENTAL
Intervention: Beta-blockers
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Calcium channel blockers
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Nitrates (Nitrocompounds)
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Alpha 2-agonists
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Diltiazem (intra-operative infusion)
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Combination of beta-blockers and calcium channel blockers
Number of subjects: 1

Group type: COMPARATOR
Intervention: Anti-platelet agents
Number of subjects: 1
Study: 2742102

Group type: EXPERIMENTAL
Intervention: Oesophageal detector device
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (standard methods)
Number of subjects: 100
Study: 4604405

Group type: EXPERIMENTAL
Intervention: Single intravenous injection of 120 mg/sq m of hydrocortisone 2 hr prior to leukapheresis
Number of subjects: 22

Group type: COMPARATOR
Intervention: No therapy (control group)
Number of subjects: 22
Study: 29337835

Group type: EXPERIMENTAL
Intervention: Promethazine (0.3 mg/kg)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Midazolam (0.5 mg/kg)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 93
Study: 30953467

Group type: EXPERIMENTAL
Intervention: Adjuvant hepatic arterial infusion pump (HAIP) chemotherapy with 6 cycles of floxuridine, starting 4-12 weeks after surgery.
Number of subjects: 230

Group type: COMPARATOR
Intervention: Resection alone (standard of care in the Netherlands).
Number of subjects: 230
Study: 28219442

Group type: EXPERIMENTAL
Intervention: Eplerenone 25 mg orally once daily for 24 months
Number of subjects: 11
Study: 24192586

Group type: EXPERIMENTAL
Intervention: Computer-based cognitive training intervention
Number of subjects: 51

Group type: COMPARATOR
Intervention: Measurement-only control
Number of subjects: 51
Study: 22830537

Group type: EXPERIMENTAL
Intervention: Aluminum oxide sandblasting followed by silorane resin composite
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Aluminum oxide sandblasting followed by methacrylate resin composite
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Acid treatment with methacrylate resin composite
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: No treatment
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Diamond bur abrasion
Number of subjects: 108

Group type: COMPARATOR
Intervention: Control (solid resin composite)
Number of subjects: 108
Study: 21508527

Group type: EXPERIMENTAL
Intervention: Background music
Number of subjects: 89

Group type: COMPARATOR
Intervention: No background music
Number of subjects: 89
Study: 18974713

Group type: EXPERIMENTAL
Intervention: Hypohydrated (HH) in warm chamber (37+/‐0.5 degrees C; RH = 70%)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Euhydrated (EH) in warm chamber (37+/‐0.5 degrees C; RH = 70%)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Hypohydrated (HH) in room temperature (22+/‐1 degrees C; RH = 50%)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Euhydrated (EH) in room temperature (22+/‐1 degrees C; RH = 50%)
Number of subjects: 10
Study: 17488148

Group type: EXPERIMENTAL
Intervention: Quetiapine 300 mg/day
Number of subjects: 0
Study: 15081457

Group type: EXPERIMENTAL
Intervention: Thalidomide
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Thalidomide (reduced dose)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control group (no thalidomide)
Number of subjects: 200
Study: 11876941

Group type: EXPERIMENTAL
Intervention: Glutamine (Gln) granules, 10 grams three times a day for 10 days
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo, 10 grams three times a day for 10 days
Number of subjects: 20
Study: 9662679

Group type: EXPERIMENTAL
Intervention: staff-assisted intervention
Number of subjects: 874

Group type: EXPERIMENTAL
Intervention: staff-counseling intervention
Number of subjects: 874

Group type: COMPARATOR
Intervention: standard care control
Number of subjects: 874
Study: 7877895

Group type: EXPERIMENTAL
Intervention: Beta-carotene supplementation for three months
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 2908483

Group type: EXPERIMENTAL
Intervention: esmolol 195 +/- 10 micrograms/kg/min (n = 15)
Number of subjects: 25

Group type: COMPARATOR
Intervention: nitroprusside 1.9 +/- 0.3 micrograms/kg/min (n = 10)
Number of subjects: 25
Study: 29752398

Group type: EXPERIMENTAL
Intervention: Watchman device implantation
Number of subjects: 1739
Study: 27816856

Group type: EXPERIMENTAL
Intervention: School-based health and nutrition intervention with peer-led behavior change communication and health promotion through school media and health clubs.
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned).
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Intervention group vs Control group at midline and endline.
Number of subjects: 1000